Advisory Cmte. Endorses Cinryze Unanimously, But HAE Battle Continues

Even with a unanimous endorsement from FDA's Blood Products Advisory Committee, Lev Pharmaceuticals' hereditary angioedema candidate Cinryze has an uncertain future because of competitive pressure - as several companies are racing to win FDA's orphan drug exclusivity for HAE

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet